Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-ascending-dose safety and pharmacokinetic study of IndUC in healthy adult men
jRCT2051260210Phase 1Recruiting
- Start
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of indigo naturalis in autoimmune colitis (4 arms), sponsored by none. Primary endpoints: Safety evaluation parameters, Adverse events and serious adverse events and 5 more. Started Nov 2026; status: recruiting.
02
Drugs
indigo naturalis
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2051260210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260210.